SwitchGear Genomics Launches Industry’s First Cost-Effective Research Tool for Screening Entire Nuclear Receptor and Hypoxia Pathways
High-throughput human promoter assays enable researchers to measure transcriptional regulation across every gene in a pathway
MENLO PARK, Calif. – December 11, 2008 – SwitchGear Genomics Inc., a leading provider of products for studying the regulatory elements in the human genome, today announced the availability of the industry’s first cost-effective high-throughput research tool for screening the transcriptional activation in the nuclear receptor and hypoxia gene pathways. The Nuclear Receptor Pathway Set™ and Hypoxia Pathway Set™ enable researchers to independently measure the impact of a stimulus on the transcriptional activation of each gene in a regulatory network.
The new SwitchGear pathway sets measure the activity of both the known and novel promoters related to nuclear receptor and hypoxia pathways. The Nuclear Receptor Pathway Set contains assay-ready luciferase reporter constructs for more than 1,000 nuclear receptor promoters and their targets. Subsets include promoter targets for PPARs, estrogen, androgen and glucocorticoid receptors. The Hypoxia Pathway Set has nearly 200 reporter constructs and provides a wide-ranging list of transcriptional promoters related to hypoxia biology, as well as promoters of genes associated with inflammation, respiration, vascular biology and novel promoters containing the hypoxia response element (HRE).
"By providing an assay-ready resource, SwitchGear enables our customers to focus not on making but using promoter reporter constructs for the comprehensive investigation of gene regulatory networks across many different experimental conditions," said Shelley Force Aldred, Ph.D., co-founder and president of SwitchGear Genomics. "The Nuclear Receptor Pathway Set and Hypoxia Pathway Set are delivered as purified transfection-ready plasmid DNAs. Customers now have the option of receiving complete sets, creating a customized subset based on our gene lists or selecting individual constructs."
For more information on SwitchGear’s Nuclear Receptor Pathway Set and Hypoxia Pathway Set or to take advantage of the company’s current year-end promotion, please visit www.switchgeargenomics.com.
About SwitchGear Genomics, Inc.:
SwitchGear Genomics Inc. is a leading provider of products for studying the regulatory elements in the human genome. The company has developed a comprehensive approach to generate new insights into gene regulatory networks and allow researchers to efficiently screen entire pathways in living cells. SwitchGear was founded in March 2005 by Dr. Richard Myers, Dr. Nathan Trinklein and Dr. Shelley Force Aldred from Stanford University. For more information about SwitchGear, please visit the company’s website at www.switchgeargenomics.com.
Contact:
Brian McKelligon
Vice President, Sales and Marketing
SwitchGear Genomics, Inc.
Phone: 650-323-6570
Email: brianm@switchgeargenomics.com
SOURCE: SwitchGear Genomics, Inc.